Lymphatica Medtech | Raises seven-digit Series A round
Share this article
LymphoDRAIN product: advance in clinical trials & improve the usability and digitisation
LYMPHATICA Medtech, a vascular medical device development start-up, closes a seven-digit financing round to advance clinical validation aiming at revolutionising the treatment of chronic lymphoedema. The investment round was led by the High Tech Gründerfonds, a large and experienced German VC fund that will accompany them on their way forward. The EIT Health contributed to the financement, funding development activities to improve the usability and digitalisation of its product, LymphoDRAIN. The funds will be used to advance in the roadmap to bring LymphoDRAIN to lymphedema patients.
LYMPHATICA Medtech SA is a Swiss medical device company founded in July 2017. It is a spin-off of the Swiss Federal Institute of Technology, Lausanne (EPFL) and of the Lausanne University Hospital (CHUV ). The Company vision is to become the leader in the development and marketing of innovative medical devices for the treatment of lymphatic diseases. LYMPHATICA has been supported by a number of institutions and programs, including the European Commission (EIC pilot), Innosuisse (Swiss Innovation Agency), FIT (Foundation for Technological Innovation), Canton Vaud (SPEI), VentureKick, Venture Leaders, MassChallenge (Gold Award) and >>venture>> (Business Plan Award).
Full Press Release.